The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Managing patients with ‘difficult-to-treat’ myeloma
Marc Raab, MD, German Cancer Research Center, Heidelberg, Germany, discusses treatment strategies for difficult-to-treat multiple myeloma (MM) patient populations, such as those with renal insufficiency, frail patients, and multi-refractory cases. Prof. Raab highlights the importance of examining specific cohorts within trial data to identify effective combination therapies and mentions the potential of extended quadruplet and triple induction/consolidation therapy to improve progression-free survival (PFS) in high-risk patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
